Literature DB >> 34998630

Degree of change in right ventricular adaptation measures during axillary Impella support informs risk stratification for early, severe right heart failure following durable LVAD implantation.

Brian Hsi1, Denny Joseph2, Barry Trachtenberg1, Arvind Bhimaraj1, Erik E Suarez1, Jiaqiong Xu3, Ashrith Guha4, Ju H Kim5.   

Abstract

Risk assessment for early, severe right heart failure (RHF) after LVAD implantation remains imperfect. We sought to define the differences in RV adaptation and load after axillary Impella support between patients who experienced RHF and those who did not. Seventeen of 18 patients included were deemed intermediate or high risk for RHF by EUROMACS-RHF score. Before Impella insertion, RV adaptation parameters (RAP, RAP:PCWP, PAPi) were worse in the non-RHF group compared to the RHF group. In both groups, RV load parameters (effective pulmonary arterial elastance, pulmonary vascular resistance, and pulmonary vascular compliance) improved after Impella insertion. Lesser improvements in RV adaptation were seen in the RHF group. Moreover, load-to-adaptation relationships (EA/RAP and EA/RAP:PCWP) worsened to a greater degree. In patients at intermediate or high risk for RHF after LVAD, assessment of RV adaptation and load during axillary Impella support may improve risk stratification.
Copyright © 2021 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Impella; LVAD; Right heart failure

Mesh:

Year:  2021        PMID: 34998630     DOI: 10.1016/j.healun.2021.11.007

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  2 in total

1.  Pulmonary Artery Pulsatility Index and Hemolysis during Impella-Incorporated Mechanical Circulatory Support.

Authors:  Makiko Nakamura; Teruhiko Imamura; Yuki Hida; Koichiro Kinugawa
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

2.  Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.

Authors:  Nazzareno Galiè; Sean Gaine; Richard Channick; J Gerry Coghlan; Marius M Hoeper; Irene M Lang; Vallerie V McLaughlin; Cheryl Lassen; Lewis J Rubin; Shu-Fang Hsu Schmitz; Olivier Sitbon; Victor F Tapson; Kelly M Chin
Journal:  Adv Ther       Date:  2021-10-30       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.